Alveolar CleftNCT06621719
Evaluation of Secondary Alveolar Cleft Reconstruction
A study testing Alveolar Cleft Reconstruction in people with Alveolar Cleft, run by Beni-Suef University at 1 site in Egypt.
Trial summary
The rehabilitation of the disorganized maxilla is the primary objective of secondary alveolar bone grafting (SABG) for alveolar clefts, as the bony reconstruction of the discontinued maxillary arch would permit proper anterior teeth eruption, improve their orthodontic movements, restore the nasal and alar base… Read more about this study
- Who is it for?
- Ages 9 to 14 yearsHealthy volunteers can take part
- Conditions the study is for
- Alveolar Cleft
- What is being tested?
- Alveolar Cleft Reconstruction
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- 1 siteEgypt
- Study dates
- 7 Nov 2024to 14 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 14 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Patients of both sexes with unilateral secondary maxillary alveolar cleft, during the mixed dentition stage with an age range of (eight to twelve years old)
- Good general good health and proper state of oral hygiene.
Who cannot join
- The detection of maxillary pathosis or palatal fistulae during the radiographic or clinical examination.
- Patients with systemic disorders that would compromise the bone harvest or graft outcomes, those with cleft-associated syndromes or a history of previous failed (SABG)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Secondary Alveolar Cleft Reconstruction Using Bone Matrix Prepared From Cancellous Particulates Mixed With Albumin-PRF or L-PRF: (A Randomized Controlled Clinical Trial)
The rehabilitation of the disorganized maxilla is the primary objective of secondary alveolar bone grafting (SABG) for alveolar clefts, as the bony reconstruction of the discontinued maxillary arch would permit proper anterior teeth eruption, improve their orthodontic movements, restore the nasal and alar base symmetry, counteract the growth disturbance effects and seal the oronasal communication. By the time the transverse growth of the maxillary arch is nearly complete during the mixed dentition stage, (SABG) intends to bridge the maxillary continuity by a quantitative bone graft entity that minimizes the maxillary collapse and growth impairment after an appropriate separation and elevation of the nasal and mucosal flaps.
Read the detailed description
By its ample content of subcutaneous autogenous cancellous bone particulates, the iliac crest is considered the gold standard for (SABG) of alveolar clefts, with optimal restoration of the maxillary continuity, and fair subsequent teeth eruption, orthodontic movements or implant placement. However, several studies have demonstrated that the final volume of the sole iliac crest particulate graft is unpredictable.
Sohn et al. in 2010 introduced the growth-factors enriched bone matrix "sticky bone" concept that incorporates the platelet-rich fibrin (PRF) into the particulate grafts to enhance their moldability and enrich them with three-dimensional (3D) fibrin networking scaffold and high concentrations of growth factors, which promote cell division, modulate tissue healing and induce angiogenesis, such as vascular endothelial growth factors (VEGF), recombinant human platelet-derived growth factor (rhPDGF), transforming growth factors ß-1 (TGFß-1), bone morphogenic protein-2 (rhBMP2), insulin growth factor-I (IFG-I), and epithelial growth factor (EGF), and interleukins.
During the last decade, various (PRF) preparations and centrifuge protocols have been developed, forming various platelet products with different biological constitutions and potential applications. The (PRF) evolution began with the development of the leukocyte- and platelet-rich fibrin (L-PRF) by an increased centrifuge time and speed, followed by advanced platelet-rich fibrin (A-PRF), injectable platelet-rich fibrin (I-PRF), horizontal platelet-rich fibrin (H-PRF), Concentrated PRF (C-PRF) and most recently the albumin-PRF (Albumin gel).
The (L-PRF) employs the extract of the platelet-rich plasma (PRP) in the form of a fibrin clot, meanwhile discarding the platelet-poor plasma (PPP). On the other hand, the albumin gel preparation employs the aspiration and heating of the platelet-poor plasma (PPP), the upper layer, then remixing it with the (PRP) layer and the buffy coat; the lower layers, after being allowed to cool. Although the heating and cooling process would threaten the vitality of cells and the growth factor of the (PPP) layer, this will polymerize its plasmatic proteins and denature the high albumin content as a result of the replacement of the weak hydrogen bond linkages within the protein molecule, with densely organized ones, in addition to the formation of thermal aggregate cross-linkage fibrin networks with an overall endured mechanical strength, prolonged degradation time up to 4-6months, and extended release of growth factors up to ten days.
- Conditions
- Alveolar Cleft
- Being tested
- Alveolar Cleft Reconstruction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alveolar Cleft ReconstructionProcedure or surgery
Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
| Study group | Role | What they receive |
|---|---|---|
| Control group (L-PRF) | Active comparator | The tubes will be centrifuged at (700 g for 12 min). By the end of the centrifuge cycle, the PRF clots will be extruded from the tubes with a sterile tweezer and separated from the underlying RBCs with sterile scissors. Receives: Procedure: Alveolar Cleft Reconstruction |
| Study group (Albumin-PRF) | Active comparator | The tubes will be centrifuged at (700 g for 8 minutes). The upper (PPR) layer will be aspirated through the unremoved plastic cap, collected in a 2-ml plastic syringe, and placed into a bio-heat device for heating at (75°C for 10 minutes) for the purpose of albumin gel formation, which will be allowed to cool for an additional ten minutes into the room temperature in a sealed dark container before being mixed with the liquid PRF and buffy coat lower layers, using a female-female luer lock connector Receives: Procedure: Alveolar Cleft Reconstruction |
What is being measured
The primary outcome is the main question the study is designed to answer.
The graft fill rate
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period.
Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Measured: 6 months
The graft resorption rate
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period.
Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Measured: 6 months
The bone bridge formation rate
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period.
Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Measured: 6 months
Bone bridge density values:
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period.
Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start7 Nov 2024
- Primary completion1 Oct 2025
- Study completion14 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alveolar CleftStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This clinical trial introduces a radiographic volumetric and bone density comparison of alveolar clefts obliterated with "sticky bone," prepared by mixing iliac crest cancellous bone particulates with either L-PRF (Control group) or Albumin-PRF (Study group).
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Nagi Alghandour, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06621719
- Sponsor's protocol ID
- 23
- Status last verified
- Nov 2025
- First submitted
- 29 Sep 2024
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Secondary Alveolar Cleft Reconstruction Using Bone Matrix Prepared From Cancellous Particulates Mixed With Albumin-PRF or L-PRF: (A Randomized Controlled Clinical Trial)
- ClinicalTrials.gov ID
- NCT06621719
- Acronym / sponsor ID
- 23
- Conditions
- Alveolar Cleft
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 7 Nov 2024 (actual)
- Primary completion
- 1 Oct 2025 (actual)
- Study completion
- 14 Nov 2025 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The rehabilitation of the disorganized maxilla is the primary objective of secondary alveolar bone grafting (SABG) for alveolar clefts, as the bony reconstruction of the discontinued maxillary arch would permit proper anterior teeth eruption, improve their orthodontic movements, restore the nasal and alar base symmetry, counteract the growth disturbance effects and seal the oronasal communication. By the time the transverse growth of the maxillary arch is nearly complete during the mixed dentition stage, (SABG) intends to bridge the maxillary continuity by a quantitative bone graft entity that minimizes the maxillary collapse and growth impairment after an appropriate separation and elevation of the nasal and mucosal flaps.
Detailed description
By its ample content of subcutaneous autogenous cancellous bone particulates, the iliac crest is considered the gold standard for (SABG) of alveolar clefts, with optimal restoration of the maxillary continuity, and fair subsequent teeth eruption, orthodontic movements or implant placement. However, several studies have demonstrated that the final volume of the sole iliac crest particulate graft is unpredictable.
Sohn et al. in 2010 introduced the growth-factors enriched bone matrix "sticky bone" concept that incorporates the platelet-rich fibrin (PRF) into the particulate grafts to enhance their moldability and enrich them with three-dimensional (3D) fibrin networking scaffold and high concentrations of growth factors, which promote cell division, modulate tissue healing and induce angiogenesis, such as vascular endothelial growth factors (VEGF), recombinant human platelet-derived growth factor (rhPDGF), transforming growth factors ß-1 (TGFß-1), bone morphogenic protein-2 (rhBMP2), insulin growth factor-I (IFG-I), and epithelial growth factor (EGF), and interleukins.
During the last decade, various (PRF) preparations and centrifuge protocols have been developed, forming various platelet products with different biological constitutions and potential applications. The (PRF) evolution began with the development of the leukocyte- and platelet-rich fibrin (L-PRF) by an increased centrifuge time and speed, followed by advanced platelet-rich fibrin (A-PRF), injectable platelet-rich fibrin (I-PRF), horizontal platelet-rich fibrin (H-PRF), Concentrated PRF (C-PRF) and most recently the albumin-PRF (Albumin gel).
The (L-PRF) employs the extract of the platelet-rich plasma (PRP) in the form of a fibrin clot, meanwhile discarding the platelet-poor plasma (PPP). On the other hand, the albumin gel preparation employs the aspiration and heating of the platelet-poor plasma (PPP), the upper layer, then remixing it with the (PRP) layer and the buffy coat; the lower layers, after being allowed to cool. Although the heating and cooling process would threaten the vitality of cells and the growth factor of the (PPP) layer, this will polymerize its plasmatic proteins and denature the high albumin content as a result of the replacement of the weak hydrogen bond linkages within the protein molecule, with densely organized ones, in addition to the formation of thermal aggregate cross-linkage fibrin networks with an overall endured mechanical strength, prolonged degradation time up to 4-6months, and extended release of growth factors up to ten days.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This clinical trial introduces a radiographic volumetric and bone density comparison of alveolar clefts obliterated with "sticky bone," prepared by mixing iliac crest cancellous bone particulates with either L-PRF (Control group) or Albumin-PRF (Study group).
| Arm | Type | Receives |
|---|---|---|
| Control group (L-PRF) | Active comparator | Procedure: Alveolar Cleft ReconstructionThe tubes will be centrifuged at (700 g for 12 min). By the end of the centrifuge cycle, the PRF clots will be extruded from the tubes with a sterile tweezer and separated from the underlying RBCs with sterile scissors. |
| Study group (Albumin-PRF) | Active comparator | Procedure: Alveolar Cleft ReconstructionThe tubes will be centrifuged at (700 g for 8 minutes). The upper (PPR) layer will be aspirated through the unremoved plastic cap, collected in a 2-ml plastic syringe, and placed into a bio-heat device for heating at (75°C for 10 minutes) for the purpose of albumin gel formation, which will be allowed to cool for an additional ten minutes into the room temperature in a sealed dark container before being mixed with the liquid PRF and buffy coat lower layers, using a female-female luer lock connector |
Who may qualify
- Ages
- 9 to 14 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Patients of both sexes with unilateral secondary maxillary alveolar cleft, during the mixed dentition stage with an age range of (eight to twelve years old)
- Good general good health and proper state of oral hygiene.
Key exclusion criteria (2 listed)
- The detection of maxillary pathosis or palatal fistulae during the radiographic or clinical examination.
- Patients with systemic disorders that would compromise the bone harvest or graft outcomes, those with cleft-associated syndromes or a history of previous failed (SABG)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alveolar Cleft ReconstructionAlveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group | Procedure or surgery | Control group (L-PRF), Study group (Albumin-PRF) |
Primary outcome
The graft fill rate
Time frame: 6 months
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period. Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
The graft resorption rate
Time frame: 6 months
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period. Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
The bone bridge formation rate
Time frame: 6 months
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period. Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Bone bridge density values:
Time frame: 6 months
The patients will be followed up immediately after surgery and then monthly during the six-month graft consolidation period. Immediate postoperative and six-month postoperative Cone beam xray will be undertaken for the patients, which will be superimposed to compare the exact extent of vertical and horizontal bone loss between the cases of the study and control groups.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
Related trials for Alveolar Cleft
Not yet recruiting
Tertiary Alveolar Cleft Reconstruction Using Double Mandibular Cortical Bone Blocks Technique Versus Double Iliac Corticocancellous Bone Blocks Technique
Alveolar Cleft Grafting
Not yet recruitingPhase 2
Metformin and Alveolar Cleft
Alveolar Cleft
Not yet recruiting
Bilateral Alveolar Cleft Reconstruction Using Double Iliac Bone Blocks vs Particulate Grafting
Alveolar Cleft
Active, not recruiting
Assessment of Bone Volume Using Patient Specific Autogenous Bone Plug Versus Particulate Autogenous Bone for Unilateral Alveolar Ridge Reconstruction
Alveolar Cleft Grafting
Recruiting
Analgosedation With Ketamine, Nalbuphine, or Dexmedetomidine for Suture Removal in Children After Cleft Surgery
Orofacial Clefts, Cleft Lip and Palate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alveolar Cleft Reconstruction in people with Alveolar Cleft, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The graft fill rate (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025; AzTrials last refreshed its copy on 6 Nov 2026.